Emcure Pharmaceuticals Reports Strong Q2FY27 Results Led by International Growth
Emcure Pharmaceuticals Ltd 路 Investor Presentation 路 03 Nov 2026, 7:34 pm
Emcure Pharmaceuticals Reports Strong Q2FY27 Results Led by International Growth Emcure Pharmaceuticals reported Q2FY27 revenue from operations of INR 28,205 Mn, up 24.3% YoY and 9.3% QoQ, driven by a 34.5% YoY rise in international sales and 12.0% YoY growth in domestic business. EBITDA rose 30.9% YoY to INR 5,748 Mn, with margins expanding 103 bps to 20.4%. PAT increased 29.3% YoY to INR 3,251 Mn with an 11.5% margin. As of 30th Sep'26, RoCE expanded to 24.9%, while net debt stood at INR 13,171 Mn due to Mantra earnouts and Gennova consolidation payments.
Original exchange filing (PDF)
More announcements from Emcure Pharmaceuticals Ltd
- Intimation of Cancellation of schedule of Analyst / Investor Meeting(s) scheduled on November 16, 2026 路 15 Nov 2026
- Transcript of Earnings Call - Q2 FY27 held on Tuesday, November 03, 2026 at 4:00 p.m. (IST) 路 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026 路 06 Nov 2026
- Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026 路 06 Nov 2026
- Audio recording of Earnings Call - Q2 FY27 路 04 Nov 2026
- Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026 路 03 Nov 2026
- Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 03 Nov 2026
- For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026. 路 03 Nov 2026
